Biopsy Devices Market Research Report by Product (Localization Wires, Needle-based Biopsy Instruments, and Procedure Trays), by Technique (MRI-guided Biopsy, Stereotactic-guided Biopsy, and Ultrasound-guided Biopsy), by Application, by End-user – Global Forecast to 2025 – Cumulative Impact of COVID-19New York, March 29, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Biopsy Devices Market Research Report by Product, by Technique, by Application, by End-user – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05993441/?utm_source=GNW Market Statistics:The report provides market sizing and forecast across five major currencies – USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.1. The Global Biopsy Devices Market is expected to grow from USD 2,166.70 Million in 2020 to USD 3,111.69 Million by the end of 2025.2. The Global Biopsy Devices Market is expected to grow from EUR 1,899.80 Million in 2020 to EUR 2,728.38 Million by the end of 2025.3. The Global Biopsy Devices Market is expected to grow from GBP 1,688.93 Million in 2020 to GBP 2,425.54 Million by the end of 2025.4. The Global Biopsy Devices Market is expected to grow from JPY 231,241.95 Million in 2020 to JPY 332,096.17 Million by the end of 2025.5. The Global Biopsy Devices Market is expected to grow from AUD 3,146.33 Million in 2020 to AUD 4,518.58 Million by the end of 2025.Market Segmentation & Coverage:This research report categorizes the Biopsy Devices to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Product, the Biopsy Devices Market studied across Localization Wires, Needle-based Biopsy Instruments, and Procedure Trays. The Needle-based Biopsy Instruments further studied across Core Biopsy Devices and Vacuum-assisted Biopsy Devices. Based on Technique, the Biopsy Devices Market studied across MRI-guided Biopsy, Stereotactic-guided Biopsy, and Ultrasound-guided Biopsy. Based on Application, the Biopsy Devices Market studied across Breast Biopsy, Colorectal Biopsy, Lung Biopsy, and Prostate Biopsy. Based on End-user, the Biopsy Devices Market studied across Academic and Research Institutes, Diagnostic and Imaging Centers, and Hospitals. Based on Geography, the Biopsy Devices Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Biopsy Devices Market including Angiotech Pharmaceuticals, Inc., Argon Medical Devices, Inc., B. Braun Melsungen AG, Becton, Dickinson and Company, Boston Scientific Corporation, C. R. Bard, Inc., Cardinal Health, Inc., Cook Group Incorporated, Creganna, Devicor Medical Products, Inc., DTR Medical Ltd, Focal Therapeutics, Inc., Fujifilm Holdings Corporation, Gallini S.r.l., Hologic, INC., Inrad, Inc., Integra LifeSciences Corporation, Leica Biosystems, Medtronic PLC, Olympus Corporation, Precision Biopsy, LLC, Scion Medical Technologies, LLC, and TSK Laboratory Europe BV. Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biopsy Devices Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Biopsy Devices Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biopsy Devices Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biopsy Devices Market?4. What is the competitive strategic window for opportunities in the Global Biopsy Devices Market?5. What are the technology trends and regulatory frameworks in the Global Biopsy Devices Market?6. What are the modes and strategic moves considered suitable for entering the Global Biopsy Devices Market?Read the full report: https://www.reportlinker.com/p05993441/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
TOKYO (AP) — Japanese technology group SoftBank swung back to profitability in the July-September quarter, boosted by positive results in its Vision Fund investments.
Tokyo-based SoftBank Group Corp. reported Tuesday a fiscal second quarter profit of nearly 1.18 trillion yen ($7.7 billion), compared with a 931 billion yen loss in the year-earlier period.
Quarterly sales edged up about 6% to nearly 1.77 trillion yen ($11.5 billion).
SoftBank credited income from royalties and licensing related to its holdings in Arm, a computer chip-designing company, whose business spans smartphones, data centers, networking equipment, automotive, consumer electronic devices, and AI applications.
The results were also helped by the absence of losses related to SoftBank’s investment in office-space sharing venture WeWork, which hit the previous fiscal year.
WeWork, which filed for Chapter 11 bankruptcy protection in 2023, emerged from Chapter 11 in June.
SoftBank has benefitted in recent months from rising share prices in some investment, such as U.S.-based e-commerce company Coupang, Chinese mobility provider DiDi Global and Bytedance, the Chinese developer of TikTok.
SoftBank’s financial results tend to swing wildly, partly because of its sprawling investment portfolio that includes search engine Yahoo, Chinese retailer Alibaba, and artificial intelligence company Nvidia.
SoftBank makes investments in a variety of companies that it groups together in a series of Vision Funds.
The company’s founder, Masayoshi Son, is a pioneer in technology investment in Japan. SoftBank Group does not give earnings forecasts.
Shopify Inc. executives brushed off concerns that incoming U.S. President Donald Trump will be a major detriment to many of the company’s merchants.
“There’s nothing in what we’ve heard from Trump, nor would there have been anything from (Democratic candidate) Kamala (Harris), which we think impacts the overall state of new business formation and entrepreneurship,” Shopify’s chief financial officer Jeff Hoffmeister told analysts on a call Tuesday.
“We still feel really good about all the merchants out there, all the entrepreneurs that want to start new businesses and that’s obviously not going to change with the administration.”
Hoffmeister’s comments come a week after Trump, a Republican businessman, trounced Harris in an election that will soon return him to the Oval Office.
On the campaign trail, he threatened to impose tariffs of 60 per cent on imports from China and roughly 10 per cent to 20 per cent on goods from all other countries.
If the president-elect makes good on the promise, many worry the cost of operating will soar for companies, including customers of Shopify, which sells e-commerce software to small businesses but also brands as big as Kylie Cosmetics and Victoria’s Secret.
These merchants may feel they have no choice but to pass on the increases to customers, perhaps sparking more inflation.
If Trump’s tariffs do come to fruition, Shopify’s president Harley Finkelstein pointed out China is “not a huge area” for Shopify.
However, “we can’t anticipate what every presidential administration is going to do,” he cautioned.
He likened the uncertainty facing the business community to the COVID-19 pandemic where Shopify had to help companies migrate online.
“Our job is no matter what comes the way of our merchants, we provide them with tools and service and support for them to navigate it really well,” he said.
Finkelstein was questioned about the forthcoming U.S. leadership change on a call meant to delve into Shopify’s latest earnings, which sent shares soaring 27 per cent to $158.63 shortly after Tuesday’s market open.
The Ottawa-based company, which keeps its books in U.S. dollars, reported US$828 million in net income for its third quarter, up from US$718 million in the same quarter last year, as its revenue rose 26 per cent.
Revenue for the period ended Sept. 30 totalled US$2.16 billion, up from US$1.71 billion a year earlier.
Subscription solutions revenue reached US$610 million, up from US$486 million in the same quarter last year.
Merchant solutions revenue amounted to US$1.55 billion, up from US$1.23 billion.
Shopify’s net income excluding the impact of equity investments totalled US$344 million for the quarter, up from US$173 million in the same quarter last year.
Daniel Chan, a TD Cowen analyst, said the results show Shopify has a leadership position in the e-commerce world and “a continued ability to gain market share.”
In its outlook for its fourth quarter of 2024, the company said it expects revenue to grow at a mid-to-high-twenties percentage rate on a year-over-year basis.
“Q4 guidance suggests Shopify will finish the year strong, with better-than-expected revenue growth and operating margin,” Chan pointed out in a note to investors.
This report by The Canadian Press was first published Nov. 12, 2024.
TORONTO – RioCan Real Estate Investment Trust says it has cut almost 10 per cent of its staff as it deals with a slowdown in the condo market and overall pushes for greater efficiency.
The company says the cuts, which amount to around 60 employees based on its last annual filing, will mean about $9 million in restructuring charges and should translate to about $8 million in annualized cash savings.
The job cuts come as RioCan and others scale back condo development plans as the market softens, but chief executive Jonathan Gitlin says the reductions were from a companywide efficiency effort.
RioCan says it doesn’t plan to start any new construction of mixed-use properties this year and well into 2025 as it adjusts to the shifting market demand.
The company reported a net income of $96.9 million in the third quarter, up from a loss of $73.5 million last year, as it saw a $159 million boost from a favourable change in the fair value of investment properties.
RioCan reported what it says is a record-breaking 97.8 per cent occupancy rate in the quarter including retail committed occupancy of 98.6 per cent.
This report by The Canadian Press was first published Nov. 12, 2024.
